List of Figures
Figure 1: Epigenetic Therapeutics Market, Global, Revenue Forecast ($m) 2009–2017
Figure 2: Epigenetic therapeutics Market, by Geography, Revenue Forecast ($m) 2009–2017
Figure 3: Epigenetic Therapeutics Market, The US, Revenue Forecast ($m) 2009–2017
Figure 4: Epigenetic Therapeutics Market, Europe, Revenue Forecast ($m), 2009–2017
Figure 5: Epigenetic Therapeutics Market, Japan, Revenue Forecast ($m) 2009–2017
Figure 6: Vidaza, Global, Revenue Forecast ($m) 2009–2017
Figure 7: Vidaza, By Geography, Revenue Forecast ($m) 2009–2017
Figure 8: Vidaza, The US, Revenue Forecast ($m) 2009–2017
Figure 9: Vidaza, Europe, Revenue Forecast ($m) 2009–2017
Figure 10: Vidaza, Japan, Revenue Forecast ($m), 2009–2017
Figure 11: Vidaza Market Potential, Global, Revenue Forecast ($m), 2012–2017
Figure 12: Vidaza Market Potential, By Geography, Revenue Forecast ($m), 2012–2017
Figure 13: Vidaza Market Potential, The US, Revenue Forecast ($m), 2012–2017
Figure 14: Vidaza Market Potential, Europe, Revenue Forecast ($m), 2012–2017
Figure 15: Vidaza Market Potential, Japan, Revenue Forecast ($m), 2012–2017
Figure 16: Vidaza (Azacitidine) – Drug Pipeline, by Phase, 2010
Figure 17: Vidaza (Azacitidine) – Drug Pipeline, by Indication, 2009
Figure 18: Vidaza (Azacitidine) – Drug Pipeline, by Phase and Indication, 2010
Figure 19: Dacogen , Global, Revenue Forecast ($m), 2009–2017
Figure 20: Dacogen, By Geography, Revenue Forecast ($m), 2009–2017
Figure 21: Dacogen, The US, Revenue Forecast ($m), 2009–2017
Figure 22: Dacogen, Europe, Revenue Forecast ($m), 2009–2017
Figure 23: Dacogen, Japan, Revenue Forecast ($m), 2009–2017
Figure 24: Dacogen, Market Potential, Global, Revenue Forecast ($m), 2012–2017
Figure 25: Dacogen Market Potential, By Geography, Revenue Forecast ($m), 2012–2017
Figure 26: Dacogen Market Potential, The US, Revenue Forecast ($m), 2012–2017
Figure 27: Dacogen Market Potential, Europe, Revenue Forecast ($m), 2012–2017
Figure 28: Dacogen Market Potential, Japan, Revenue Forecast ($m), 2012–2017
Figure 29: Dacogen (Decitabine) – Drug Pipeline, by Phase, 2010
Figure 30: Dacogen (Decitabine) – Drug Pipeline, by Indication, 2010
Figure 31: Dacogen (Decitabine) – Drug Pipeline, by Phase and Indication, 2010
Figure 32: Zolinza, Global, Revenue Forecast ($m), 2010–2017
Figure 33: Zolinza, Global, Revenue Forecast ($m), 2010–2017
Figure 34: Zolinza, The US, Revenue Forecast ($m), 2010–2017
Figure 35: Zolinza, Europe, Revenue Forecast ($m), 2010–2017
Figure 36: Zolinza, Japan, Revenue Forecast ($m), 2010–2017
Figure 37: Zolinza Market Potential, Global, Revenue Forecast ($m), 2012–2017
Figure 38: Zolinza, Market Potential, By Geography, Revenue Forecast ($m), 2012–2017
Figure 39: Zolinza Market Potential, The US, Revenue Forecast ($m), 2012–2017
Figure 40: Zolinza Market Potential, Europe, Revenue Forecast ($m), 2012–2017
Figure 41: Zolinza Market Potential, Japan, Revenue Forecast ($m), 2012–2017
Figure 42: Zolinza (vorinostat) – Drug Pipeline, by Phase, 2010
Figure 43: Zolinza (vorinostat) – Drug Pipeline, by Indication, 2009
Figure 44: Zolinza (vorinostat) – Drug Pipeline, by Phase and Indication, 2010
Figure 45: Istodax Market Potential, Global, Revenue Forecast ($m), 2010–2017
Figure 46: Istodax Market Potential, By Geography, Revenue Forecast ($m), 2012–2017
Figure 47: Istodax Market Potential, The US, Revenue Forecast ($m), 2012–2017
Figure 48: Istodax Market Potential, Europe, Revenue Forecast ($m), 2012–2017
Figure 49: Istodax Market Potential, Japan, Revenue Forecast ($m), 2012–2017
Figure 50: Istodax (Romidepsin) – Drug Pipeline, by Phase, 2010
Figure 51: Istodax (Romidepsin) – Drug Pipeline, by Indication, 2010
Figure 52: Istodax (Romidepsin) – Drug Pipeline, by Phase and Indication, 2010
Figure 53: SWOT, Merck & Co, 2010
Figure 54: SWOT, Celgene Corporation, 2010
Figure 55: SWOT, Eisai, 2010
Figure 56: GBI Research Market Forecasting Model